Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Lymphocytic Leukemia, Chronic Clinical Trials

A listing of Lymphocytic Leukemia, Chronic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (369) clinical trials

PK PD Safety Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia

This is a two-part study intended to provide investigators and sponsor with the following information regarding the investigational new drug MT-3724: Part 1[COMPLETED]: in patients with relapsed/refractory non-Hodgkin's B cell lymphoma (including SLL) OR relapsed/refractory B-cell CLL The maximum dose of a single course of MT-3724 given as intravenous (IV) ...

Phase

Treosulfan Fludarabine Phosphate and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

PRIMARY OBJECTIVES: I. Graft failure/rejection and secondary graft failure. II. Day -200 non-relapse mortality. SECONDARY OBJECTIVES: I. Platelet engraftment by six months. II. Grade II-IV and III-IV acute graft-versus-host disease (GVHD) at day 100 and one year. III. Chronic GVHD. IV. Clinically significant infections. V. Overall survival. VI. Relapse or ...

Phase

Study to Evaluate Safety and Preliminary Efficacy of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

The purpose of this study is to evaluate the clinical safety and preliminary efficacy of MOR00208 combined with idelalisib or venetoclax. The study will include safety run-in phase for each cohort with an evaluation of the safety data by an Independent Data Monitoring Committee.

Phase

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) of adoptive cellular immunotherapy using ex vivo transduced and expanded autologous T cells expressing a third (3rd)-generation fully human CD20-specific chimeric antigen receptor (CAR) in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma (B-NHL). SECONDARY OBJECTIVES: I. To evaluate ...

Phase

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Chronic lymphocytic leukemia (CLL) with TP53 deletion (17p-) and/or mutation has a poor prognosis. Different therapeutic strategies have been tested over the last decade such as fludarabine-based regimens, alemtuzumab, bendamustine alone or with rituximab, lenalidomide, or ofatumumab, but all without compelling evidence for success. For example, with the FCR regimen ...

Phase

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

This is a phase I clinical trial to evaluate the safety, tolerability, and maximum tolerated dose of DMF in patients with chronic lymphocytic leukemia. Patients with relapsed/refractory CLL not amenable to available therapies are eligible. This patient population is in need of novel therapies, particularly if progressing after, intolerant of, ...

Phase

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

PRIMARY OBJECTIVES: I. Evaluate the safety and feasibility of administering sirolimus and mycophenolate mofetil (MMF) as prophylaxis of grade III-IV acute graft versus host disease (aGvHD) in patients undergoing mismatched unrelated and related donor hematopoietic stem cell transplant (HSCT). OUTLINE Patients receive sirolimus orally (PO) starting on day -3, 3 ...

Phase

Filgrastim Cladribine Cytarabine and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PRIMARY OBJECTIVES: I. To assess the maximum tolerated dose (MTD) of sorafenib (sorafenib tosylate) used in combination with dose-intensified mitoxantrone (mitoxantrone hydrochloride) as part of the G-CSF, cladribine, cytarabine and mitoxantrone hydrochloride (G-CLAM) regimen in adults with newly-diagnosed acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS). (Phase 1) II. To determine ...

Phase

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Patients who participate will be asked to complete detailed family and medical history questionnaires initially, with a follow-up questionnaire every year. Patients will be asked to supply a blood sample and possibly a mouthwash sample, both of which can be done by mail. Patients will be asked to consent to ...

Phase N/A

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination ...

Phase